SCHEMBL15859705

SCHEMBL15859705

O=c1[nH]cnc2c(O)cc(-c3cncnc3)cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 6/20 0.56
BCL2 P10415 1/20 0.53
MCL1 Q07820 1/20 0.53
PARP1 P09874 6/20 0.42
AURKA O14965 2/20 0.39
TTK P33981 1/20 0.39
AURKB Q96GD4 1/20 0.39
INCENP Q9NQS7 1/20 0.39
ACVR1 Q04771 3/20 0.36
KDM4A O75164 2/20 0.36
KDM4B O94953 2/20 0.36
KDM5C P41229 2/20 0.36
KDM5B Q9UGL1 2/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
IP6K3 Q96PC2 1/20 0.36
IP6K2 Q9UHH9 1/20 0.36
DAPK3 O43293 1/20 0.36
JAK2 O60674 1/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL15846201 0.90 IP6K1 (0.48) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15845892 0.82 IP6K1 (0.62) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15845735 0.82 IP6K1 (0.70) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15845715 0.79 BCL2 (0.56) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15846755 0.79 IP6K1 (0.63) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15846038 0.79 IP6K1 (0.60) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15845964 0.79 IP6K1 (0.60) IP6K1BCL2MCL1PARP1IP6K3
SCHEMBL15846641 0.79 IP6K1 (0.53) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15845636 0.79 IP6K1 (0.56) IP6K1BCL2MCL1PARP1AURKA
SCHEMBL15845869 0.78 IP6K1 (0.49) IP6K1BCL2MCL1PARP1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP claimed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 US disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 IP6K1 4247/4885BCL2 3842/4885MCL1 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.